Pilot study shows high detection concordance of MRD in AML patients using blood and bone marrow samples, suggesting the need for assay standardization.
Key Points
This research aims to evaluate the effectiveness of NGS-based methods for detecting measurable residual disease (MRD) in acute myeloid leukemia (AML).
Conducted a pilot study with 23 AML patients using matched bone marrow and blood samples.
Examined two NGS-based MRD assays (Assay A and Assay B) at three timepoints during treatment.
Assessed MRD positivity using variant allele frequency thresholds and defined pathogenic mutations.
Assay A showed 57% MRD positivity compared to 33% for Assay B.
High concordance in MRD detection: 83.8% for Assay A and 86% for Assay B.
Longitudinal analysis indicated stable MRD status in most patients, despite some showing dynamic changes.